SCHEMBL4712308

SCHEMBL4712308

CC(C)(C)[Si](C)(C)Oc1ccc2c3c(c(=O)oc2c1)CCCCC3

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
STS P08842 15/20 0.61
KDM4E B2RXH2 4/20 0.59
ALDH1A1 P00352 4/20 0.59
HPGD P15428 4/20 0.59
HSD17B10 Q99714 4/20 0.59
TSHR P16473 3/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CYP19A1 P11511 1/20 0.59
CA4 P22748 1/20 0.59
CA6 P23280 1/20 0.59
CA5A P35218 1/20 0.59
CA7 P43166 1/20 0.59
CA9 Q16790 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
CA14 Q9ULX7 1/20 0.59
CA5B Q9Y2D0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14514741 0.89 MEN1 (0.52) MEN1KMT2ASTSKDM4EALDH1A1
SCHEMBL14514724 0.86 ALDH1A1 (0.50) MEN1KMT2ASTSKDM4EALDH1A1
SCHEMBL4709135 0.84 MEN1 (0.48) MEN1KMT2ASTSKDM4EALDH1A1
SCHEMBL4709560 0.83 MEN1 (0.47) MEN1KMT2ASTSKDM4EALDH1A1
SCHEMBL13921229 0.80 KMT2A (0.44) MEN1KMT2ASTSKDM4EALDH1A1
SCHEMBL13921226 0.79 KMT2A (0.43) MEN1KMT2ASTSKDM4EALDH1A1
SCHEMBL29853363 0.79 MAPT (0.63) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL26781086 0.79 MAPT (0.63) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL5114194 0.78 MEN1 (0.43) MEN1KMT2ASTSKDM4EALDH1A1
SCHEMBL8124201 0.78 CA12 (0.45) MEN1KMT2ASTSKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812417-B1 NOVEL 2H-CHROMENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2008-10-29 EP disclosed
EP-1812417-A1 NOVEL 2H-CHROMENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP disclosed
US-20060166933-A1 Novel 2H-chromene derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-27 US disclosed
WO-2006055694-A1 NOVEL 2H-CHROMENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166933-A1 Novel 2H-chromene derivatives as selective estrogen receptor modulators ESR2, ESR1, GPER1 MEN1 4456/4885KMT2A 1599/4885STS 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.